Ignite Creation Date:
2025-12-24 @ 11:34 PM
Ignite Modification Date:
2026-01-01 @ 11:58 PM
Study NCT ID:
NCT06888856
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-03-21
First Post:
2025-03-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of Patients
Sponsor:
Tel-Aviv Sourasky Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-03-19
Start Date Type:
ESTIMATED
Primary Completion Date:
2030-03-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2031-03-03
Completion Date Type:
ESTIMATED
First Submit Date:
2025-03-17
First Submit QC Date:
None
Study First Post Date:
2025-03-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-03-17
Last Update Post Date:
2025-03-21
Last Update Post Date Type:
ACTUAL